top of page
Green Circle Wellness

NAD+ IV Therapy: 113 Studies, No Outcome Trials, FDA Warning

Oct 15
12 min read

Patient receiving an NAD+ IV infusion

The best available evidence does not yet support NAD+ IV therapy as a proven anti-aging or wellness treatment. A 2025 systematic review of 113 studies found no eligible outcomes trials for it, and the FDA has warned about compounded NAD+ injectables. Read on for the evidence, the safety picture, and the questions to ask any clinic.

 

TL;DR:  
  • One randomized trial reported improved heart function after seven days of NAD+ in patients with ischemic cardiomyopathy, but its findings do not establish wellness benefits.

  • A retrospective comparison linked NAD+ infusions to more moderate or severe symptoms, including nausea and chest pressure, and longer sessions than NR infusions.

  • Because the FDA has warned about compounded NAD+ injections, ask which pharmacy supplies each batch and verify injectable grade, sterility, and a certificate of analysis.

  • Clinics have no evidence based wellness dose or maintenance schedule; track energy, sleep, focus, and mood before treatment, then reassess after the initial series.

 



Table of Contents

 

 

What is NAD+ IV therapy, and how does it differ from oral NR and NMN?

 

NAD+ (nicotinamide adenine dinucleotide) is a molecule involved in cellular processes, including energy metabolism. Its role in these processes is part of the biological rationale behind NAD+ products.

 

NAD+ IV therapy delivers the molecule itself directly into a vein, usually over several hours. The rationale clinics give is that intravenous delivery bypasses digestion. Whether this means more NAD+ reaches the tissues people hope to affect is not established. That sounds logical, but the human data are more complicated than the pitch.

 

A pilot study of a 6-hour IV NAD+ infusion tracked the NAD+ metabolome in plasma and urine. Infused NAD+ was cleared from plasma quickly during at least the first two hours, with a large rise appearing only at the end of the infusion. The researchers also found NAD+ and a metabolite called meNAM in urine, which points to a complex metabolic fate rather than a clean deposit into cells. In other words, “more in the bloodstream” does not automatically mean “more inside the tissues you care about.”

 

Oral precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) take a different route. They are precursors that the body can use in NAD+ metabolism. The practical contrast looks like this when considering different oxygen delivery methods, including adjunctive noninvasive recovery options like oxygen therapy vs supplemental oxygen.

 

  • Delivery: IV NAD+ goes straight to the blood; NR and NMN pass through digestion and metabolism first.

  • Experience: IV NAD+ requires a clinic visit and a slow infusion; oral precursors are taken at home.

  • Tolerability: IV NAD+ is associated with more noticeable infusion symptoms, covered in the safety section below.

  • Regulatory footing: compounded IV NAD+ carries specific FDA concerns that do not apply the same way to a capsule.

 

So when people search for NAD vs NMN, the honest answer is that they are different tools aimed at the same biochemical pool. IV NAD+ has not been shown to produce anti-aging outcomes for wellness use, and an outcomes advantage over other approaches has not been demonstrated.

 

What benefits do people seek from NAD+ IV therapy?

 

Clinics and wellness communities tend to describe the same cluster of goals. Here is what people most often hope to get:

 

  • More energy: the most common claim, tied to NAD+'s role in mitochondrial energy production.

  • Sharper thinking: reduced “brain fog” and better focus.

  • Anti-aging effects: slower biological aging, often framed around sirtuin pathways.

  • Faster recovery: from exercise, illness, or periods of heavy stress.

  • Metabolic support: better blood sugar handling and body composition.

  • Mood and sleep: a general sense of feeling better, sometimes described as a “reset.”

 

There is real science behind the reasoning. NAD+ is a required cofactor in energy metabolism, and sirtuins, a family of enzymes linked to aging research, depend on it. Raising NAD+ in cells is a plausible way to support those systems, which is why researchers keep studying it.

 

Plausible is not the same as proven, though. A 2020 review of NAD pharmacology concluded that NAD strategies are promising but that only a small number of adequately powered clinical trials exist, and that more studies are needed to settle the best delivery methods and target conditions. That gap between mechanism and outcome is the single most important thing to understand when you read a clinic’s menu of benefits.

 

Where does human evidence stand today? Some small studies show changes in blood biomarkers after NAD+ or precursor dosing, which confirms the body responds chemically. What is largely missing are trials showing that those changes translate into things you would notice or that matter for health: lasting energy, better cognition, slower aging, or lower disease risk. Where a benefit has shown up, it has mostly been in specific patient groups under study conditions, not in healthy people seeking a wellness boost. Treat any promise of dramatic, guaranteed results as marketing, not medicine.

 

What does the clinical evidence actually say?

 

The most useful way to read this literature is from the top down: the broadest review first, then the smaller studies that fill in detail.

 

The systematic review. A 2025 PRISMA-guided review titled “NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence” covered 113 studies. It found no eligible outcomes trials evaluating intravenous or intramuscular NAD+ for anti-aging or wellness, and it concluded that clinical effectiveness for those purposes remains inconclusive.

 

113 studies reviewed, and none were eligible outcomes trials of IV or intramuscular NAD+ for anti-aging or wellness. The popular use case has not yet been tested in the kind of trial that could prove it works.

 

Tolerability data. A retrospective pilot study published in 2026 compared commercially administered NAD+ IV with NR IV in a real-world setting. NAD+ IV was linked to more moderate-to-severe infusion-related symptoms and longer infusion times. NR IV produced milder experiences. Both groups showed no significant changes in typical safety labs over 30 days, which is reassuring on short-term lab safety but says nothing about benefit.

 

Pharmacokinetics. The 6-hour infusion pilot described earlier established how infused NAD+ behaves in the body and reported overall safety and tolerability for the regimen used. It is a measurement study, not an efficacy trial.

 

A trial in a specific disease. A randomized, placebo-controlled trial in patients with ischemic cardiomyopathy reported that 7 days of intravenous NAD+ produced a statistically significant improvement in left ventricular ejection fraction at 1 month compared with placebo. That is an encouraging signal for a particular heart-failure population. It does not tell us anything about whether a healthy person receiving an infusion for energy or longevity will benefit.

 

Taken together, here is what the evidence supports and what it does not:

 

  • Supported: NAD+ can be infused, measured, and tolerated by many people, and the biology is understood.

  • Supported: NAD+ IV is associated with more infusion symptoms than NR IV in one real-world comparison.

  • Suggestive, not settled: a possible benefit in a specific cardiac population.

  • Not demonstrated: improved energy, cognition, or aging outcomes in healthy adults from IV NAD+.

 

The limits matter as much as the findings. Many studies are small. Several are retrospective, meaning researchers looked back at records instead of assigning treatments in advance. Follow-up is often short, dosing varies widely, and the NAD+ used in clinics comes from different compounding sources with different quality controls. Larger randomized outcomes trials, with standardized dosing and meaningful endpoints, are what the field still needs. Until then, anyone telling you NAD+ IV is “clinically proven” for anti-aging is getting ahead of the data.

 

Is NAD+ IV therapy safe? Side effects and compounding risks

 

Short answer: many people tolerate it, but “tolerate” often means getting through some unpleasant moments, and the product-quality question is just as important as the infusion itself.

 

Common infusion reactions

 

NAD+ is frequently described as hard to tolerate when given intravenously. Reported symptoms include:

 

  • Abdominal cramping, nausea, and vomiting

  • Chest pressure or tightness

  • Increased heart rate (tachycardia)

  • Flushing and general discomfort

 

In the retrospective comparison, NAD+ IV was associated with moderate-to-severe gastrointestinal symptoms, faster heart rate, and chest pressure, and it needed longer infusion times than NR IV. If you experience chest pressure or a racing heart during an infusion, alert the clinic staff and seek immediate medical attention.

 

Why compounding quality matters

 

NAD+ is not approved by the FDA for intravenous use, so clinics generally rely on compounded versions. That puts a lot of weight on the compounding pharmacy. The FDA has reminded compounders to use ingredients suitable for sterile compounding and has identified pharmacies misbranding compounded NAD+ injections and failing to meet sterile-compounding requirements.

 

The core danger is straightforward. Food-grade or dietary-supplement-grade bulk powders are not processed to injectable standards and can carry a high risk of microbial and endotoxin contamination when put into a vein. The FDA has made the same point about another popular wellness infusion ingredient in its alert on dietary supplement grade glutathione for injectables, noting that such products can cause severe adverse events from contamination.


Illustration of injectable ingredient quality risks

Real-world failures have occurred. A nationwide recall by Olympia Pharmacy involved seven compounded products found out of specification, including NAD among other injectables. In 2026, an FDA warning letter to Thrive Health and Wellness described specific compounded NAD+ products as unapproved new drugs and misbranded, noting that repackaged products lacked adequate directions for use. The agency also keeps a running page of compounding risk alerts and urges clinicians to report adverse events through MedWatch.

 

Responsibility for quality sits with the prescribing clinic and the compounding facility. That is why the checks below are not optional extras.

 

Safety checks you can make

 

  • Ask which compounding pharmacy supplies the NAD+ and confirm it by name.

  • Ask for a certificate of analysis (COA) for the batch.

  • Confirm the ingredient is injectable grade, not a supplement-grade powder.

  • Ask how the product was sterilized and stored.

  • Confirm that vital signs are monitored and that emergency equipment and protocols are on site.

 

Pro Tip: If a clinic cannot or will not tell you where its NAD+ comes from, treat that as your answer and walk away.

 

What happens during an NAD+ IV session?

 

No standardized protocol for NAD+ IV is established. Practices can differ from one clinic to the next, and the available evidence does not establish a wellness dose.

 

Duration follows from tolerability. Because fast infusion tends to trigger cramping, nausea, and chest pressure, clinics typically run NAD+ slowly, and sessions can last several hours. Reports from clinical settings, including the tolerability comparison in which NAD+ required longer infusion times than NR, support the idea that slower is more comfortable. The research infusion in the pharmacokinetic pilot ran for a full 6 hours.

 

A well-run session generally follows this sequence:

 

  1. Screening and consent. A clinician reviews your history, medications, and allergies, and explains the unproven nature of the therapy for wellness goals.

  2. Baseline check. Staff record blood pressure, heart rate, and how you feel before starting.

  3. IV placement. A nurse or clinician places the line and begins at a low infusion rate.

  4. Rate adjustment. The rate is raised gradually and slowed or paused if you report nausea, cramping, flushing, or chest pressure.

  5. Ongoing monitoring. Staff check vitals and ask about symptoms at intervals throughout the infusion.

  6. Aftercare. Once the line is removed, you are observed briefly, given guidance on hydration and rest, and told whom to contact if symptoms return.

 

Practical preparation helps. Eat a light meal beforehand, drink water, bring something to occupy several hours, and plan not to drive or work immediately if you feel off. Speak up early about any discomfort, because slowing the drip is the main tool for making the infusion bearable.

 

How often do people get NAD+ IV, and does it last?

 

Some clinics may offer a series of infusions followed by less frequent sessions, but this pattern has not been established as effective for sustaining an effect. The details may vary, and the available evidence does not establish an optimal schedule. No trial has established the ideal spacing, total number of sessions, or dose for wellness goals.

 

What does the research offer on durability? The small and retrospective studies we have focus on short windows. The tolerability study followed safety labs over 30 days, and the heart-failure trial assessed ejection fraction at 1 month after a 7-day course. Neither tells you how long an energy boost or cognitive change might persist. Long-term outcome data for healthy people simply do not exist yet.

 

Since the evidence cannot tell you how often to go, you need your own way to judge value:

 

  • Set a baseline before starting. Rate energy, sleep, focus, and mood on a simple 1 to 10 scale, and ask your clinic about relevant lab work.

  • Define success in advance. Decide what change would justify continuing, such as getting through the afternoon without a crash.

  • Track consistently. Log the same measures weekly, not just on infusion days.

  • Reassess after the loading series. If you see no meaningful change, that is useful information.

  • Watch for placebo effects. Expectation and a calm, attentive appointment can make anyone feel better, so lean on measurable markers where possible.

 

Continuing indefinitely on the strength of a vague feeling is the easiest way to spend a lot without learning anything.

 

Who might be a candidate, and who should be cautious?

 

Candidacy is a clinical decision, not a lifestyle choice. A clinician needs to review your health history, medications, and goals before recommending any infusion. For a healthy adult hoping for more energy or healthy aging, the honest framing is that the benefit is unproven and the burden is real, so the decision should be made with full information and no pressure.

 

Discuss your medical history, pregnancy or breastfeeding status, allergies, and medications with a clinician before considering an infusion. The available information here does not establish which conditions make NAD+ IV unsafe or appropriate. If you experience chest pressure or a racing heart during an infusion, seek immediate medical attention.

 

It also helps to understand who the studies actually enrolled. The randomized trial showing improved ejection fraction involved patients with ischemic cardiomyopathy, a defined and serious heart condition. Those results do not generalize to healthy people, and they do not imply a heart benefit for someone without that diagnosis.

 

When it is appropriate, baseline labs or medical clearance before starting are reasonable, particularly if you have heart, kidney, or liver concerns. Ask the clinic how it assesses your health history and whether an infusion is appropriate for you.

 

What should you ask a clinic before booking NAD+ IV?

 

Bring this checklist to your first call or consultation. Clear, specific answers are a good sign. Vague ones are not.

 

Sourcing and quality

 

  • Which compounding pharmacy supplies your NAD+, and can I see a certificate of analysis for the current batch?

  • Is the ingredient injectable grade, and how is sterility verified?

 

People and preparedness

 

  • Who places the IV and monitors me, and what are their credentials?

  • What emergency equipment and protocols do you have on site if I react badly?

  • What do you do if I develop chest pressure, a racing heart, or severe nausea?

 

Measuring benefit

 

  • How will we decide whether this is working?

  • What follow-up visits or lab monitoring do you offer?

  • What is the full cost of a loading series, and what are the package terms?

 

Pro Tip: Ask for the answers in writing. A reputable clinic will have no problem putting its sourcing and monitoring standards on paper.

 

A perspective on offering NAD+ IV responsibly

 

Here is where we land: NAD+ IV therapy sits in a gap between interesting biology and proven outcomes, and our job is to be honest about that gap. We start with testing and a multidisciplinary assessment, we obtain informed consent that states plainly what is and is not known, and we check the source of every compounded product we use. Monitoring is part of every infusion, not an add-on. If the evidence does not support a promise, we do not make it, and if NAD+ is not right for you, we say so.

 

— Dina

 

How we deliver IV therapy safely at Green Circle Wellness

 

Our IV Therapy & Injectables service is part of an integrative practice built on evidence-driven protocols and a team that works together on your case. At a first consultation, we take time to understand your history, goals, and medications, explain what the research does and does not show, and build a plan around you rather than a menu. We pair that with careful checks on how compounded products are sourced and with monitoring during every session.


Greencirclewellness

If you want to talk through whether NAD+ IV fits your situation, schedule a consultation through our services page, and we will take it from there.

 

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

 

FAQ

 

Does NAD IV therapy really work?

 

For anti-aging and general wellness, the evidence is not there yet. A 2025 systematic review of 113 studies found no eligible outcomes trials of IV or intramuscular NAD+ for those goals and called effectiveness inconclusive. Small studies in specific conditions, like heart failure, show signals worth following up.

 

What is the downside of taking NAD+?

 

The most common downside with IV delivery is how it feels: cramping, nausea, chest pressure, and a faster heart rate during the infusion, which typically ease when it is slowed or stopped. The second concern is product quality, since the FDA has warned about compounded NAD+ injections made with unsuitable ingredients.

 

Is NAD similar to Ozempic?

 

No. NAD+ is a molecule involved in cellular energy metabolism, while Ozempic is a prescription medication that works on appetite and blood sugar hormones. NAD+ has not been shown to produce the weight-loss effects of that drug class, so the two should not be treated as interchangeable.

 

What is NAD+ in IV therapy?

 

It is a compounded form of the NAD+ molecule delivered directly into a vein, usually over a slow, multi-hour infusion. Clinics offer it because NAD+ supports energy metabolism, but the FDA has noted that NAD+ is not approved for intravenous use, so product sourcing and monitoring matter.

 

How is NAD+ IV different from NMN or NR supplements?

 

NMN and NR are precursors the body converts into NAD+ after you swallow them, while IV NAD+ goes straight into the bloodstream. In one real-world comparison, IV NAD+ caused more moderate-to-severe infusion symptoms than IV NR.

 

Sources

 

Recommended

 

 

This article is for education only and is not medical advice.

 
 
 

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page